Abstract:1055 Lung cancer is one of the most deadly diseases worldwide and more than 50% of lung cancers contain p53 mutations. Mutant p53 can be classified into two major types, the type I (contact) mutation and type II (conformational) mutation. Important differences between these types have been established, including a higher oncogenic potential for the type II mutation, and the conservation of some wild type activity for type I. We previously established a line of lung specific SPC-p53(273H), a type I p53 mutant, which spontaneously developed lung adenocarcinomas at a median age of 13-15 months. To investigate the role of type II p53 mutant in lung tumorigenesis, a transgenic mouse model with a human mutant p53(175H, Arg to His at codon 175, a type II mutant) was developed. The transgene was placed under the control of the human surfactant protein C (SPC) promoter to selectively express the mutant gene in lung tissue. Transgenic mice were generated by microinjection of a 6.7-kb fragment of the SPC-p53 construct into the pro-nuclei of FVB/N mouse zygotes. Four transgenic founders were identified; 3 females and 1 male. Two female mice did not pass the transgene, whereas the other two passed the transgene to the F1 generation, permitting to establish a line of SPC-p53(175H) transgenic mice. The ratio of transgenic to non-transgenic offspring was 38% (N=157). Expression of the human mutant p53(175H) in lung tissue was evaluated by immunohistochemistry and Western blot analysis using the human specific p53 antibody (DO-7). These analyses showed a high level of human p53 protein in the transgenic lung tissues. The mutant protein was found primarily in the nuclei of pneumocytes from the transgenic mice, and absent in lung tissue from non-transgenic littermates. The male founder developed a lung tumor (12 mm in diameter), identified pathologically as an adenocarcinoma, at necropsy at the age of 12 months. One of the F1 males also developed a lung adenocarcinoma (11mm in diameter) at the age of five months. The remaining mice will be evaluated for the rate of tumor formation at age intervals of 7-9, 10-12 and 13-15 months and compared to the incidence in non-transgenic littermates and type I mutants. The animal models discussed above should provide valuable information on the role of mutant p53 type in lung carcinogenesis and may provide a framework to further evaluate environmental carcinogens and the effects of these mutations on response to treatment interventions.

Expression of a Mutant P53 in Lung Specific Transgenic Mice Cause Age-Related Demographic Shift in Lung Tumor Incidence

Establishment and Characterization of a Line of Transgenic Mice Harboring a Lung Specific Human Type II P53(175h) Mutation

High incidence of lung, bone, and lymphoid tumors in transgenic mice overexpressing mutant alleles of the p53 oncogene

Abstract 2988: Loss of Rbm38 Cooperates with Mutant P53 to Promote Lymphomagenesis Through Downregulation of Pten

p53 mutant mice that display early ageing-associated phenotypes

Alterations Of The P53 Tumor-Suppressor Gene In Transformed Mouse-Liver Cells

Expression of a P53 Mutant in the Epidermis of Transgenic Mice Accelerates Chemical Carcinogenesis

Gain of Function of a p53 Hot Spot Mutation in a Mouse Model of Li-Fraumeni Syndrome

Effects of genetic background on tumorigenesis in p53-deficient mice

Aging-associated truncated form of p53 interacts with wild-type p53 and alters p53 stability, localization, and activity.

The gain of function of p53 cancer mutant in promoting mammary tumorigenesis

p53 governs an AT1 differentiation programme in lung cancer suppression

Abstract LT06: Understanding the Role of Mutant TP53 in Lung Cancer Using Novel Genetically Engineered Mouse Models

[Clinical Significance of Mutant P53 Protein Expression in Lung Adenocarcinoma].

Loss of p53-mediated cell-cycle arrest, senescence and apoptosis promotes genomic instability and premature aging

Mutagenesis in Vivo in T Cells of P21-Deficient Mice

BAC transgenic mice provide evidence that p53 expression is highly regulated in vivo

Chromosome Stability, in the Absence of Apoptosis, is Critical for Suppression of Tumorigenesis in Trp53 Mutant Mice

Mice Deficient In Rbm38, A Target Of The P53 Family, Are Susceptible To Accelerated Aging And Spontaneous Tumors

Insights into Allosteric Mechanisms of the Lung-Enriched P53 Mutants V157F and R158L.

Aflatoxin-B Exposure Does Not Lead To P53 Mutations But Results In Enhanced Liver Cancer Of Hupki (Human P53 Knock-In) Mice